Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Pipeline Review, H2 2018 – ResearchByMarkets.com

September 14, 2018 /ResearchByMarkets/— “Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Pipeline Review, H2 2018

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic. 

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular and Oncology which include indications Dyslipidemia, Acute Coronary Syndrome, Cardiovascular Disease, Coronary Disease and Hyperlipidemia. 

The latest report Cholesteryl Ester Transfer Protein – Pipeline Review, H2 2018, outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/34156

Scope

– The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
– The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
– The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects 
– The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
– The report summarizes all the dormant and discontinued pipeline projects 
– The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
– Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies 
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape 
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

BUY THIS REPORT:
https://www.researchbymarkets.com/paynow/34156

Companies Mentioned: 
Chong Kun Dang Pharmaceutical Corp
DalCor Pharmaceuticals Inc
Kowa Co Ltd
Pfizer Inc

Get in touch with us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.